Three Arch Partners

Total investments

128

Average round size

18M

Portfolio companies

71

Rounds per year

4.27

Lead investments

16

Follow on index

0.45

Exits

39

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareMobileHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeutics

Summary

Three Arch Partners appeared to be the VC, which was created in 1993. The company was established in North America in United States. The leading representative office of defined VC is situated in the Portola Valley.

This organization was formed by Thomas Fogarty, Wilfred Jaeger. We also calculated 2 valuable employees in our database.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Three Arch Partners, startups are often financed by InterWest Partners, Investor Growth Capital Limited, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, Investor Growth Capital Limited, Frazier Healthcare Partners. In the next rounds fund is usually obtained by Accuitive Medical Ventures, Polaris Partners, Investor Growth Capital Limited.

The average startup value when the investment from Three Arch Partners is 10-50 millions dollars. Considering the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2014. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2007. This Three Arch Partners works on 2 percentage points less the average amount of lead investments comparing to the other organizations.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Biotechnology, Health Diagnostics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline AcuFocus, Cameron Health, Arbor Surgical Technologies

Show more

Investments analytics

Analytics

Total investments
128
Lead investments
16
Exits
39
Rounds per year
4.27
Follow on index
0.45
Investments by industry
  • Health Care (106)
  • Biotechnology (69)
  • Medical Device (64)
  • Medical (50)
  • Manufacturing (21)
  • Show 27 more
Investments by region
  • United States (125)
  • Belgium (3)
Peak activity year
2008

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
20
Avg. valuation at time of investment
54M
Group Appearance index
0.95
Avg. company exit year
11
Avg. multiplicator
1.47
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Arete Therapeutics 19 Nov 2008 Biotechnology, Health Care, Therapeutics Early Stage Venture 16M United States, California, Hayward
Saite 25 Nov 2019 Robotics, Navigation, Industrial Automation Early Stage Venture 3M Guangdong Province, Huangpu District, China
Salveo Specialty Pharmacy 13 Oct 2011 Biotechnology, Health Care, Medical Early Stage Venture United States, Florida, Saint Petersburg

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.